What's happened
Global markets show a sharp reversal as momentum stocks lose ground in July after AI-driven gains earlier in 2026. Chipmakers weaken, biotech surges on Moderna news, and investors reassess valuations as sector rotations intensify amid a choppy August.
What's behind the headline?
Core Dynamics
- AI-driven momentum has cooled: the S&P 500 Momentum Index has weakened while the broader S&P 500 has posted modest gains.
- Sector rotation is underscored by memory-chip firms lagging after a July sell-off and biotech catching a bid on Moderna’s trial results.
- Valuation concerns are resurfacing, prompting traders to reassess risk and adjust exposures.
What This Signals
- A potential shift from momentum-led performance to more selective stock picking across AI-adjacent sectors.
- Increased volatility risk as investors rebalance portfolios amid divergent sector trajectories.
- The market is relying on earnings visibility and durable growth narratives to justify valuations in a high-priced environment.
How we got here
Investors priced in a powerful AI-led rally across 2024–2026, pushing momentum indices higher even as broader markets paused near record levels. The latest quarter has seen a rotation out of hot AI-related names, with memory-chip makers among the hardest hit and biotech rallying on Moderna’s late-stage melanoma vaccine results, reshaping sentiment and positioning.
Our analysis
Business Insider UK notes a deepening unwind in the momentum trade as AI-driven gains loosen and biotech stocks regain momentum after Moderna’s results. CNBC highlights August’s subdued trading ranges and Nvidia’s impact on sentiment, while Independent documents the broader macro backdrop, including oil price swings and the enduring effects of the war on markets.
Go deeper
- What sectors are most at risk as momentum fades?
- How should investors reposition for a potential re-acceleration in AI stocks?
- What role does biotech play in this rotation?